# A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza

> **NCT03336619** · PHASE3 · COMPLETED · sponsor: **Romark Laboratories L.C.** · enrollment: 1030 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Nitazoxanide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03336619
- **Lead sponsor:** Romark Laboratories L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-17
- **Primary completion:** 2019-04-17
- **Final completion:** 2019-04-17
- **Target enrollment:** 1030 (ACTUAL)
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03336619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03336619, "A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03336619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*